Global Cancer Immunotherapy Market to Grow at a CAGR of 9.7% During 2022-2027, Aided by the Heightened Prevalence of Cancer

The global market for cancer immunotherapy is being driven by the increased prevalence of various types of cancer such as breast, lung, prostate, colorectal, and liver cancer. With 19.3 million cases reported in 2020, cancer remained the second leading cause of death worldwide. As a result, the demand for effective cancer immunotherapy treatment to strengthen the patient's immune response against cancer-causing viruses has surged. Moreover, with the growing geriatric population worldwide, governments are increasingly investing in healthcare infrastructure to reduce the mortality risks associated with chronic diseases like cancer. The rapid diagnosis of diseases and the growing awareness about the advantages of immunotherapy over conventional treatment methods are providing impetus to the market expansion. Immunotherapy is accompanied by minimal side effects that can be managed safely if addressed early. Additionally, it gives the possibility for long-term control of cancer as it trains the immune system to remember cancer cells, which can result in potentially permanent protection against cancer recurrence. The growing investments in research activities to develop new immunotherapies are contributing to the market development. For instance, in December 2021, scientists at the University of Oslo developed a new type of immunotherapy for cancer that makes the patient's immune cells remember that cancer is a transplanted organ that should be rejected. The efficiency of the new treatment was demonstrated on patient leukaemia cells and in mouse models and the researchers are aiming to conduct a clinical trial in patients with acute leukaemia. Over the forecast period, the advancement in genetic engineering is likely to aid the market for cancer immunotherapy.

The growing focus of the leading players to develop advanced clinical solutions to fight cancer-causing viruses is expected to positively impact the market growth in the forecast period. In July 2021, Amgen Inc. (NASDAQ: AMGN) announced the acquisition of multispecific immunotherapy biotech startup, TeneoBio, which is in the process of developing multispecific and bispecific molecules, including biologics known as human-chain antibodies.

Market Breakup by Therapy Type, Application, End Use, and Region:

• The market is categorised, based on therapy type, into monoclonal antibodies, cancer vaccines, immunomodulators, and immune check point inhibitors, among others.
• On the basis of application, the market can be divided into prostate cancer, breast cancer, skin cancer, and lung cancer, among others.
• Based on end use, the market can be segmented into hospitals and clinics, cancer research centres, and others.
• Region-wise, the global market for cancer immunotherapy can be divided into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

Key Findings of the Report:

• The global market for cancer immunotherapy is being driven by the heightened prevalence of cancer worldwide.
• The increasing awareness regarding cancer and its potential prevention has significantly contributed to the market expansion.
• The rapid implementation of immunotherapy in the treatment of different types of cancers is also aiding the market development.
• The growing investments in research and development activities to develop new immunotherapy treatments are further propelling the market growth.

Key Offerings of the Report:

• The EMR report gives an overview of the global market for cancer immunotherapy for the periods (2017-2021) and (2022-2027). 
• The report also offers historical (2017-2021) and forecast (2022-2027) market information for the therapy types, applications, end uses, and regions of cancer immunotherapy.
• The report analyses the market dynamics, covering the key demand and price indicators in the market, along with providing an assessment of the SWOT and Porter’s Five Forces models.

The major players in the global cancer immunotherapy market are Amgen Inc., Astellas Pharma Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, and F. Hoffmann-La Roche AG., among others. The comprehensive report by EMR looks into the market share, capacity, and latest developments like mergers and acquisitions, plant turnarounds, and capacity expansions of the major players.

About Us

Expert Market Research (EMR) is a leading market research and business intelligence company, ensuring its clients remain at the vanguard of their industries by providing them with exhaustive and actionable market data through its syndicated and custom market reports, covering over 15 major industry domains. The company's expansive and ever-growing database of reports, which are constantly updated, includes reports from industry verticals like chemicals and materials, food and beverages, energy and mining, technology and media, consumer goods, pharmaceuticals, agriculture, and packaging.

EMR leverages its state-of-the-art technological and analytical tools, along with the expertise of its highly skilled team of over 100 analysts and more than 3000 consultants, to help its clients, ranging from Fortune 1000 companies to small and medium-sized enterprises, easily grasp the expansive industry data and help them in formulating market and business strategies, which ensure that they remain ahead of the curve.

Contact Us:

Expert Market Research
Website: www.expertmarketresearch.com
Email: sales@expertmarketresearch.com
US & Canada Phone no: +1-415-325-5166
UK Phone no: +44-702-402-5790

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.